The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy.
Micevic G, Bosenberg M, Yan Q. The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy. Clinical Cancer Research 2022, 29: 1173-1182. PMID: 36449280, PMCID: PMC10073242, DOI: 10.1158/1078-0432.ccr-22-0784.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsImmune checkpoint inhibitorsImmune checkpoint therapyT cell exhaustionCheckpoint therapyAntitumor immune responseT cell populationsCell-intrinsic immunityTypes of cancerViral mimicry responseLow response rateCheckpoint inhibitorsCurrent immunotherapiesPancreatic cancerSustained responsePreclinical modelsTreatment outcomesImmune responseEndogenous antigensResponse rateTumor typesMultiple epigenetic regulatorsCritical mediatorLow immunogenicityTherapyCancer193 Arachnoid Cysts as Genetically-encoded Harbingers of Neurodevelopmental Pathology
Kundishora A, Kiziltug E, Allington G, Allocco A, Smith H, Ocken J, Moreno-De-Luca A, DiLuna M, Jin S, Kahle K. 193 Arachnoid Cysts as Genetically-encoded Harbingers of Neurodevelopmental Pathology. Neurosurgery 2022, 68: 58-58. DOI: 10.1227/neu.0000000000001880_193.Peer-Reviewed Original ResearchGene expressionGene setsScRNAseq datasetsWhole-exome sequencingSingle-cell RNA sequencing dataExome-wide significanceCell type relationshipsMultiple epigenetic regulatorsRNA sequencing dataMulti-omics approachExome sequencingChromatin remodelingEpigenetic regulationMRNA processingPhenomic analysisEpigenetic regulatorsPhenomics techniquesIntegrative genomicsSequencing dataSignificant enrichmentGenesFirst insightPhenotypic clustersNovo variantsNovel associations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply